Key Points
- Director Shehnaaz Suliman sold 5,723 shares of 10x Genomics at an average price of $81.19, generating $464,650.37. The transaction reduced her holdings by 19.39% to 23,792 shares.
- 10x Genomics shares opened at $84.11, near their 12-month high of $85.93, while the company reported quarterly revenue of $151.04 million and an adjusted loss of $0.14 per share.
- Analysts maintain a consensus “Hold” rating with an average price target of $44.00; five analysts rate the stock a Buy, 11 a Hold and one a Sell.
10x Genomics (NASDAQ:TXG - Get Free Report) Director Shehnaaz Suliman sold 5,723 shares of the stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $81.19, for a total value of $464,650.37. Following the sale, the director owned 23,792 shares of the company's stock, valued at approximately $1,931,672.48. The trade was a 19.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shehnaaz Suliman also recently made the following trade(s):
- On Monday, August 24th, Shehnaaz Suliman sold 2,207 shares of 10x Genomics stock. The shares were sold at an average price of $63.65, for a total value of $140,475.55.
10x Genomics Stock Up 11.2%
Shares of NASDAQ TXG opened at $84.11 on Friday. 10x Genomics has a 12 month low of $11.16 and a 12 month high of $85.93. The company has a market cap of $10.96 billion, a P/E ratio of -142.56 and a beta of 2.08. The business's 50 day moving average is $59.90 and its two-hundred day moving average is $38.61.
10x Genomics (NASDAQ:TXG - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.10. The company had revenue of $151.04 million during the quarter, compared to analysts' expectations of $146.67 million. 10x Genomics had a negative return on equity of 9.33% and a negative net margin of 12.18%.10x Genomics's revenue for the quarter was down 12.7% compared to the same quarter last year. During the same period in the prior year, the business earned $0.28 earnings per share. Sell-side analysts expect that 10x Genomics will post -0.75 earnings per share for the current fiscal year.
Analyst Ratings Changes
TXG has been the subject of a number of research reports. UBS Group began coverage on shares of 10x Genomics in a report on Wednesday, September 9th. They issued a "neutral" rating and a $68.00 price target for the company. Piper Sandler upped their price objective on shares of 10x Genomics from $42.00 to $47.00 and gave the company a "neutral" rating in a research report on Monday, August 10th. TD Cowen reiterated a "hold" rating on shares of 10x Genomics in a research note on Wednesday, July 15th. Stifel Nicolaus set a $50.00 target price on 10x Genomics in a research report on Friday, August 7th. Finally, Morgan Stanley boosted their price target on 10x Genomics from $37.00 to $40.00 and gave the company an "equal weight" rating in a research note on Friday, August 7th. Five analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $44.00.
View Our Latest Report on 10x Genomics
Hedge Funds Weigh In On 10x Genomics
Several hedge funds have recently added to or reduced their stakes in TXG. Tidal Investments LLC bought a new position in 10x Genomics during the second quarter worth about $1,279,000. Integrated Wealth Concepts LLC increased its stake in shares of 10x Genomics by 34.9% in the 2nd quarter. Integrated Wealth Concepts LLC now owns 21,645 shares of the company's stock valued at $830,000 after acquiring an additional 5,595 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in shares of 10x Genomics in the 2nd quarter valued at approximately $2,069,000. Arizona State Retirement System raised its position in shares of 10x Genomics by 1.5% in the 2nd quarter. Arizona State Retirement System now owns 29,223 shares of the company's stock valued at $1,120,000 after acquiring an additional 430 shares during the period. Finally, Nykredit A S bought a new position in 10x Genomics during the 2nd quarter worth approximately $126,000. Institutional investors and hedge funds own 84.68% of the company's stock.
10x Genomics Company Profile
(
Get Free Report)
10x Genomics, Inc develops life science technology for analyzing biological systems at the single-cell and spatial levels. Its platforms are designed to help researchers study gene expression, genetic variation, cell populations and tissue organization with greater detail than conventional laboratory methods.
The company's product portfolio includes the Chromium platform for single-cell analysis, Visium solutions for spatial transcriptomics and tissue profiling, and Xenium in situ platforms for high-resolution analysis of RNA and other biological features within tissue samples.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
